Search our team at AdventHealth Research Institute
-
Comparative effectiveness of Juntos Después del Cáncer (JDC) among Breast Cancer Survivors and their Intimate Partners
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, Florida -
NCT04852887
A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE,ONCOTYPE RECURRENCE SCORE d 18 BREAST CANCER
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Altamonte, FloridaThis study is being done to answer the following question: Is treatment with hormonal therapy as good as the usual treatment of radiation and hormonal therapy in women with low-risk breast cancer who...
-
NCT02954874
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with greater than or equal to 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy.
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to compare the usual approach (no more treatment or additional chemotherapy and radiation therapy after surgery or radiation therapy alone after surgery), with any effects...
-
NCT05563220
STML-ELA-022 A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE)
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Altamonte, FloridaThis research study is being done to find out if elacestrant is safe and tolerable when given in combination with one of the following study drugs, approved in the treatment of advanced breast cancer...
-
NCT06072612
A Phase 3 Randomized, Open-label Study Comparing the Bria-IMT regimen in combination with Check Point Inhibitor vs Physician’s Choice in Metastatic Breast Cancer (BRIA-ABC)
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this research study is to assess the safety and effectiveness of an experimental therapy for advanced breast cancer called Bria-IMT (SV-BR-1-GM) in combination with the immune...
-
NCT06312176
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Altamonte, FloridaThis trial is testing MK-2870 given alone and MK-2870 given with pembrolizumab (MK-2870 plus pembro) in people with advanced breast cancer that cannot be surgically removed.
This trial will compare... -
NCT05508906
A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination with the CDK4/6 Inhibitor Ribociclib or with the PI3K Inhibitor Alpelisib in Adult Subjects with Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaParticipants will be invited to take part in this clinical research study if they have been treated for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 negative (HER2)...
-
NCT04457596
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThis study is being done to answer the following question: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing your cancer from returning...
-
NCT05514054
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Altamonte, FloridaThis study is being done to see how safe an investigational drug is and how well it will work to help people with Estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative...
-
NCT05629585
D926XC00001: Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have Residual Invasive Disease in Breast and/or Axillary Lymph Nodes Following Neoadjuvant Systemic Therapy and Surgical Resection (TROPION-Breast03)
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Altamonte, FloridaWe are doing this study to learn more about whether an investigational drug called datopotamab deruxtecan (also called Dato-DXd), either alone or in combination with another investigational drug...
-
NCT06065748
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy (pionERA Breast Cancer)
This study is not currently enrolling.Research Area: Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to compare the effects, good or bad, of two hormonal treatments, giredestrant and fulvestrant, both given in combination with your study doctor’s choice of a class of...
-
NCT06188559
BB-1701-G000-205 An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to determine if a new drug called BB-1701 is safe and effective in people who have HER2-positive or HER2-low, unresectable or metastatic breast cancer (MBC). There are two...